Axogen, Inc. Appoints John H. Johnson to Board of Directors
UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that John H. Johnson has been appointed to its Board of Directors.
RTI Surgical and Exactech Announce Strategic Partnership
UF startup and UF Innovate | Sid Martin Biotech alum RTI Surgical Holdings, Inc., a leading surgical implant company providing blue-chip OEM customers with a portfolio of tissue-based, synthetic and metal implants, has announced it has entered into a long-term strategic agreement with Gainesville-based and leading global medical device OEM Exactech, related to the development and supply of biologic bone substitutes.
Experimental Skin Cancer Vaccine Developed in Tampa Saves Woman’s Life
A vaccine developed by Morphogenesis, Inc., a UF startup and UF Innovate | Sid Martin Biotech alum, helped improve a patients condition.
dMed-Clinipace Announces Completion of US$50 Million Series C+ Financing From New Investors
dMed-Clinipace, the global full-service Clinical Contract Research Organization (CRO), announced the successful completion of a US$50 million Series C+ financing with participation from a group of new, leading international healthcare investors.
SharpSpring Founder Rick Carlson Featured on Radio Cade Podcast
When Rick Carlson founded UF startup SharpSpring in 2012, he didn't think of himself as a CEO. “My co-founder and I were doing whatever it took to survive,” Carlson says, and they were responsible for everything from software development to buying office supplies. In the early days of the automated marketing software company, “there were so many failures it was hard to name them all,” according to Carlson.
Cannabix Technologies Granted Cannabis Drug Detection Device Canadian Patent, Delivers THCBA to US Clinic
UF startup Cannabix Technologies Inc., developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the Canadian Intellectual Property Office (CIPO) has granted patent No. 2887841 entitled, “Cannabis Drug Detection Device”.
AGTC Reports 12-Month Data From Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients With Mutations in the ACHM
UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, reported 12-month data from its ongoing achromatopsia (ACHM) Phase 1/2 clinical trials, including data from all adult patients and low-dose pediatric patients.
Putting Corporate Back into Wellness Benefits with Ed Buckley of Peerfit
Ed Buckley, CEO of UF startup Peerfit, a digital health technology company, talked with Laura Cave and Mike Zarrillo, hosts of the Better Benefits podcast, about creating better wellness benefits that employees will actually use.
Atsena Therapeutics Receives Orphan Drug Designation From the FDA for Novel Gene Therapy To Treat Genetic Eye Disease LCA1
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its investigational gene therapy product for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1), a genetic eye disease that affects the retina.
Revolutionizing the Science of Nerve Repair and Regeneration
Peripheral nerve damage is estimated to affect more than 20 million people in the United States, causing symptoms that range from mild discomfort to severe disability. Damage is often undiagnosed or untreated, and the current standard of care procedures can be associated with limitations that impact the quality of life. UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair, aims to address these issues and provide more efficient treatment options to patients.
